{
  "nctId": "NCT04593641",
  "briefTitle": "This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)",
  "officialTitle": "A Pilot Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Virology of CT-P59 in Patient With Mild Symptoms of SARS-CoV-2 Infection",
  "protocolDocument": {
    "nctId": "NCT04593641",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2020-07-27",
    "uploadDate": "2021-09-13T03:04",
    "size": 1587583,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04593641/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE1"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "SEQUENTIAL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 18,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-09-04",
    "completionDate": "2021-04-05",
    "primaryCompletionDate": "2020-10-26",
    "firstSubmitDate": "2020-10-05",
    "firstPostDate": "2020-10-20"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\nEach patient must meet all of the following criteria to be randomized in this study:\n\n1. Adult male or female patient, aged between 18 to 60 years (both inclusive).\n2. Patient with laboratory confirmed SARS-CoV-2 infection by Reverse Transcription Polymerase Chain Reaction (RT-PCR) at Screening.\n3. Patient has mild conditions meeting all of the following criteria:\n\n   1. Oxygen saturation ≥ 94% on room air.\n   2. Not requiring supplemental oxygen.\n4. Onset of symptom is no more than 7 days prior to the study drug administration.\n\nExclusion Criteria:\n\n1\\. Patient with severe condition meeting one of the following:\n\n1. Respiratory distress with respiratory rate ≥ 30 breaths/min.\n2. Requires supplemental oxygen.\n3. Experience shock.\n4. Complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion.\n5. Any other conditions suspected of being severe symptoms of SARS-CoV-2 infection, in the opinion of the investigator, including but not limited to radiographic findings in lung.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "60 Years",
    "stdAges": [
      "ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Patients With TEAEs",
        "timeFrame": "Up to Day 14"
      },
      {
        "measure": "Number of Patients With Treatment-Emergent Serious Adverse Events (TESAEs)",
        "timeFrame": "Up to Day 14"
      },
      {
        "measure": "Number of Patients With Treatment-Emergent Adverse Events of Special Interest (TEAESI; Infusion Related Reactions Including Hypersensitivity/Anaphylactic Reaction)",
        "timeFrame": "Up to Day 14"
      },
      {
        "measure": "Number of Patients With Potential Effects on the Incidence of Antibody-Dependent Enhancement (ADE)",
        "timeFrame": "Up to Day 14"
      }
    ],
    "secondary": [
      {
        "measure": "The Percentage of Patients With Positive/Negative for Quantitative Polymerase Chain Reaction (qPCR)",
        "timeFrame": "At Day 28"
      },
      {
        "measure": "Duration of Viral Shedding in Nasopharyngeal Swab Specimens for qPCR",
        "timeFrame": "Up to Day 28"
      },
      {
        "measure": "Area Under the Concentration-time Curve of Viral Titers for qPCR",
        "timeFrame": "Up to Day 28"
      },
      {
        "measure": "Actual Results and Change From Baseline for Viral Shedding in Nasopharyngeal Swab Specimens for qPCR",
        "timeFrame": "Up to Day 28"
      },
      {
        "measure": "Number of Patients With Clinical Recovery",
        "timeFrame": "Up to Day 28"
      },
      {
        "measure": "Number of Patients Requiring Supplemental Oxygen",
        "timeFrame": "Up to Day 28"
      },
      {
        "measure": "Number of Patients With Intensive Care Unit Transfer",
        "timeFrame": "Up to Day 28"
      },
      {
        "measure": "Number of Mechanical Ventilation",
        "timeFrame": "Up to Day 28"
      },
      {
        "measure": "Number of Patients With All-cause Mortality",
        "timeFrame": "Up to Day 28"
      },
      {
        "measure": "Number of Patients With Hospital Admission",
        "timeFrame": "Up to Day 28"
      },
      {
        "measure": "Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of CT-P59",
        "description": "The PK parameters were calculated by noncompartmental methods based on the actual sampling time points using Phoenix WinNonlin Version 8.3 (Pharsight, St Louis, Missouri, USA).",
        "timeFrame": "Up to Day 90"
      },
      {
        "measure": "Time to Cmax (Tmax) of CT-P59",
        "description": "The PK parameters were calculated by noncompartmental methods based on the actual sampling time points using Phoenix WinNonlin Version 8.3 (Pharsight, St Louis, Missouri, USA).",
        "timeFrame": "Up to Day 90"
      },
      {
        "measure": "Dose Normalized AUC0-inf (AUC0-inf/Dose) of CT-P59 (Normalized to Total Body Dose)",
        "description": "The PK parameters were calculated by noncompartmental methods based on the actual sampling time points using Phoenix WinNonlin Version 8.3 (Pharsight, St Louis, Missouri, USA).",
        "timeFrame": "Up to Day 90"
      },
      {
        "measure": "Terminal Half-life (t1/2) of CT-P59",
        "description": "The PK parameters were calculated by noncompartmental methods based on the actual sampling time points using Phoenix WinNonlin Version 8.3 (Pharsight, St Louis, Missouri, USA).",
        "timeFrame": "Up to Day 90"
      },
      {
        "measure": "Percentage of AUC0-inf Obtained by Extrapolation (%AUCext) of CT-P59",
        "description": "The PK parameters were calculated by noncompartmental methods based on the actual sampling time points using Phoenix WinNonlin Version 8.3 (Pharsight, St Louis, Missouri, USA).",
        "timeFrame": "Up to Day 90"
      },
      {
        "measure": "Terminal Elimination Rate Constant (λz) of CT-P59",
        "description": "The PK parameters were calculated by noncompartmental methods based on the actual sampling time points using Phoenix WinNonlin Version 8.3 (Pharsight, St Louis, Missouri, USA).",
        "timeFrame": "Up to Day 90"
      },
      {
        "measure": "Total Body Clearance (CL) of CT-P59",
        "description": "The PK parameters were calculated by noncompartmental methods based on the actual sampling time points using Phoenix WinNonlin Version 8.3 (Pharsight, St Louis, Missouri, USA).",
        "timeFrame": "Up to Day 90"
      },
      {
        "measure": "Volume of Distribution During the Elimination Phase (Vz) of CT-P59",
        "description": "The PK parameters were calculated by noncompartmental methods based on the actual sampling time points using Phoenix WinNonlin Version 8.3 (Pharsight, St Louis, Missouri, USA).",
        "timeFrame": "Up to Day 90"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 4,
      "secondaryCount": 18,
      "otherCount": 0,
      "totalCount": 22
    },
    "studyDesign": {
      "phases": [
        "PHASE1"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "SEQUENTIAL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:37.271Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}